You are here: Industry Insights > rare disease

News List

CVC Capital revs up rare disease ambitions with $3.5B Recordati buyout fiercepharma
July 03, 2018
Recordati has finally sealed a sale. Private equity player CVC Capital Partners said (PDF) Friday it would drop €3.03 billion
Rare disease specialist Spectrum eyes potential $2B-plus sale: Bloomberg fiercepharma
June 29, 2018
Biopharma M&A has picked up this year with deals dominated by rare diseases and cancer, more than $34 billion all told, not counting Takeda's hefty $62 billion offer for Shire.
Inspirational patient stories reveal the challenging realities of living with devastating rare disea worldpharmanews
March 13, 2018
Boehringer Ingelheim unveils a new phase of "More Than Scleroderma: The Inside Story", and launches the new patient website www.morethanscleroderma.com.
Inspirational patient stories reveal the challenging realities of living with devastating rare disea worldpharmanews
March 01, 2018
Boehringer Ingelheim unveils a new phase of "More Than Scleroderma: The Inside Story"
Little Orphan Drugs Can Lead to Big Market Rare Disease Drugs in China zhulikou431
January 22, 2018
In the Ice Bucket Challenge in 2014, the “amyotrophic lateral sclerosis” (ALS) patients attracted the world’s attention, and more people started to pay attention to the rare diseases.
Rare disease in EU Zhulikou431
January 09, 2018
According to some information released by the European Medicines Agency (EMA), there are about 30 million people in Europe suffering from rare diseases, the incidence of most diseases less than one hundred thousandth.
Rare disease in America Zhulikou431
January 09, 2018
Rare disease is a general term for a group of diseases with a very low incidence, also known as orphan disease.
Bioverativ to purchase True North Therapeutics for $400m pharmaceutical-technology
May 27, 2017
Global biotechnology company Bioverativ has entered a definitive agreement to acquire US-based company True North Therapeutics for $400m.
Takeda and Harrington Discovery Institute to Develop Rare Disease Therapeutics americanpharmaceuticalreview
April 28, 2017
Takeda Pharmaceutical and Harrington Discovery Institute at University Hospitals in Cleveland, Ohio announced a multi-year collaboration to accelerate therapeutic discoveries in rare diseases.
Sucampo Pharmaceuticals acquires rare disease company Vtesse for $200m pharmaceutical-technology
April 06, 2017
Global biopharmaceutical company Sucampo Pharmaceuticals has acquired US-based rare disease company Vtesse in a deal valued at $200m.

Previous page 1 2 3 4 5 Next page